NeuroSense Therapeutics (NRSN) Other Non-Current Liabilities (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted Other Non-Current Liabilities of $3.8 million for Q1 2024, up 172.59% sequentially from $1.4 million in Q4 2023, and up 630.36% YoY from $527000.0 in Q2 2023.
NeuroSense Therapeutics (NRSN) Other Non-Current Liabilities (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Other Non-Current Liabilities for 4 years, with the latest figure at $3.8 million in Q1 2024.
- Quarterly Other Non-Current Liabilities rose 630.36% year-over-year to $3.8 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $3.8 million (up 630.36% YoY) and the FY2023 annual result came in at $1.4 million, up 547.71% from the prior year.
- Other Non-Current Liabilities grew to $3.8 million in Q1 2024 per NRSN's latest filing, from $1.4 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $6.3 million in Q2 2023 and troughed at $218000.0 in Q4 2022.
- A 4-year average of $1.8 million and a median of $816000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 88.07% in 2022, then jumped 812.3% in 2023.
- Over 4 years, Other Non-Current Liabilities stood at $1.8 million in 2021, then slumped by 88.07% to $218000.0 in 2022, then soared by 547.71% to $1.4 million in 2023, then soared by 172.59% to $3.8 million in 2024.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.8 million, $1.4 million, and $6.3 million for Q1 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Jun 30, 2023 | 6.30 Mn |
| Mar 31, 2023 | 527,000.00 |
| Dec 31, 2022 | 218,000.00 |
| Sep 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 691,000.00 |
| Mar 31, 2022 | 816,000.00 |
| Dec 31, 2021 | 1.83 Mn |